Fresenius Medical Care, a global leader in renal therapies, has partnered with Mexico’s Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) to broaden the availability of high-volume haemodiafiltration (HighVolumeHDF) in Mexico. This initiative is set to launch a pilot program aimed at providing haemodialysis therapies to low-income individuals lacking medical coverage.
Under the terms of a two-year agreement, Fresenius will deploy 150 of its advanced 5008S CorDiax systems across renal treatment centers in Mexico City and its metropolitan area. These systems offer both standard haemodialysis and the more advanced HighVolumeHDF, which has been shown to significantly enhance patient outcomes.
Expanding Access to Life-Saving Treatment
The collaboration has already enabled 240 new patients at CCINSHAE centers, who previously had no public or private medical insurance, to receive HighVolumeHDF treatment. This follows last year’s successful introduction of the therapy to 410 insured patients.
Edgar Robles, Managing Director of Fresenius Medical Care Mexico, stated, “The groundbreaking pilot program, with its mission to provide chronic kidney disease (CKD) patients with access to high-quality treatments that were previously out of their reach, represents an important advancement in CKD care in Mexico.”
Clinical Support and Global Reach
HighVolumeHDF is backed by numerous clinical studies, including the influential CONVINCE trial, which demonstrated a
23% average decrease in all-cause mortality for HighVolumeHDF patients compared to those receiving standard high-flux haemodialysis.
Fresenius currently offers this therapy across several countries in the Americas and plans to introduce it in the United States for kidney disease patients.
In February 2024, the company achieved a significant milestone by securing 510(k) clearance from the US Food and Drug Administration (FDA) for its 5008X Hemodialysis System, an updated version of its haemodiafiltration-capable 5008X CAREsystem. This system, featuring additional enhancements, also received 501(k) clearance earlier this year, paving the way for its commercial launch in the US market.
Implications for Healthcare in Mexico
This development comes at a critical time for Mexico’s healthcare system, which has been striving to improve access to advanced medical treatments for its underserved populations. The introduction of HighVolumeHDF in public health facilities could mark a turning point in the management of chronic kidney disease, a condition that affects millions of Mexicans.
According to healthcare experts, the success of this pilot program could lead to broader implementation across the country, potentially setting a precedent for similar initiatives in other regions. The move represents a significant step towards reducing health disparities and improving the quality of life for those affected by kidney disease.
As Fresenius continues to expand its reach, the company’s commitment to innovation and patient care remains at the forefront of its operations. The ongoing collaboration with CCINSHAE underscores the potential for public-private partnerships to drive meaningful change in healthcare delivery.
Looking ahead, the success of this initiative may inspire further collaborations between global healthcare leaders and local health authorities, ultimately fostering a more inclusive and equitable healthcare landscape.
